Feb 9 (Reuters) - Catalyst Biosciences Inc:
* CATALYST BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 1/2 STUDY OF SUBCUTANEOUS CB 2679D/ISU304 IN INDIVIDUALS WITH HEMOPHILIA B
* CATALYST BIOSCIENCES INC - ALL INDIVIDUALS WITH SEVERE HEMOPHILIA IMPROVED TO MILD HEMOPHILIA ACTIVITY LEVELS AFTER ONLY SIX DAILY DOSES
* CATALYST BIOSCIENCES - RESULTS SUGGEST LONG-TERM DOSING OF SQ CB 2679D COULD MAINTAIN STABLE CLOTTING ACTIVITY IN HIGH-MILD HEMOPHILIA TO NORMAL RANGE
* CATALYST BIOSCIENCES INC - NO INHIBITORS TO CB 2679D OR FIX WERE INDUCED TO DATE
* CATALYST BIOSCIENCES-1 SUBJECT HAD MODERATE ADVERSE EVENTS OF PAIN,ERYTHEMA,REDNESS AFTER FIRST 2 INJECTIONS, MILD RATING AFTER SUBSEQUENT INJECTIONS Source text for Eikon: Further company coverage: